Goldman Sachs Group Inc Lyra Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 334,665 shares of LYRA stock, worth $93,706. This represents 0.0% of its overall portfolio holdings.
Number of Shares
334,665
Previous 13,063
2461.93%
Holding current value
$93,706
Previous $68,000
2960.29%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LYRA
# of Institutions
82Shares Held
44.4MCall Options Held
300KPut Options Held
1.3K-
Perceptive Advisors LLC New York, NY12.8MShares$3.57 Million1.67% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.34MShares$1.21 Million0.01% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$789,8741.13% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$778,4735.45% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.74MShares$767,8880.04% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $8.91M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...